Theranostic Radiopharmaceuticals: A Universal Challenging Educational Paradigm in Nuclear Medicine
Jean-Luc Urbain(Society of Nuclear Medicine and Molecular Imaging), Richard L. Wahl(Mallinckrodt (United States)), Jolanta Kunikowska(Medical University of Warsaw), Francesco Giammarile(International Atomic Energy Agency), François Lamoureux(Centre National de la Recherche Scientifique), Helen Nadel(Helios Klinikum Emil von Behring), Mohamad Haidar(Investigators Research Group (United States)), Kyung-Han Lee(Samsung (South Korea)), Rudi Dierckx(University Medical Center Groningen), Sze Ting Lee(Amsterdam University Medical Centers), Jun Hatazawa(Osaka University of Pharmaceutical Sciences), Stuart More(South African Thoracic Society), Wolfgang Wadsak(The Research Council), Modiselle Moshe(South African Thoracic Society), Lizette Louw(South African Thoracic Society), Andrew M. Scott(Olivia Newton-John Cancer Wellness & Research Centre), Joo Hyun O(Korean Nuclear Society), Seigo Kinuya(Kanazawa University Hospital), Daniel Lee(Northwestern University), Baljinder Singh(Punjab Technical University), Andrew S. Ross(Commonwealth Scientific and Industrial Research Organisation), John Buscombe(University of Cambridge), Charlotte Weston, Diana Páez
Cited by 34
Related Papers
Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation
|Molecular Neurobiology|2018|750
Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study
|Journal of Nuclear Medicine|2009|562
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging
|Neuroendocrinology|2017|495
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
|Proceedings of the National Academy of Sciences|2004|440
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419